User: Guest  Login
More Searchfields
Simple search
Title:

Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy.

Document type:
Journal Article; Article
Author(s):
Prebet, Thomas; Cluzeau, Thomas; Park, Sophie; Sekeres, Mikkael A; Germing, Ulrich; Ades, Lionel; Platzbecker, Uwe; Götze, Katharina; Vey, Norbert; Oliva, Esther; Sugrue, Mary M; Bally, Cecile; Kelaidi, Charikleia; Al Ali, Najla; Fenaux, Pierre; Gore, Steven D; Komrokji, Rami
Abstract:
While lenalidomide (LEN) is the standard of care for the lower-risk myelodysplastic syndromes (MDS) patients with deletion 5q, 35% will not respond to or do not tolerate the drug. Moreover, most of the patients will lose their response after a few years. Defining the outcome of patients with LEN failure and determining the impact of subsequent therapies is therefore important to develop alternative strategies. Based on an international collaboration, we were able to compile a total of 392 patien...     »
Journal title abbreviation:
Oncotarget
Year:
2017
Journal volume:
8
Journal issue:
47
Pages contribution:
81926-81935
Language:
eng
Fulltext / DOI:
doi:10.18632/oncotarget.18477
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/29137233
TUM Institution:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
 BibTeX